Search the Newsreel

PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records

Schubert Jonckheer & Kolbe LLP is investigating a data breach impacting Abbott Laboratories and its subsidiary Exact Sciences Corporation. An unauthorized third party, allegedly ShinyHunters, accessed legacy cancer diagnostics systems in July 2026, potentially exfiltrating sensitive patient information including names, contact details, dates of …

Abbott Laboratories (ABT) Could Be 14% Undervalued On Mixed Earnings And Growth Focus

Abbott Laboratories (ABT) is considered 14% undervalued despite mixed Q2 2026 earnings, which showed increased sales but lower net income year-over-year. The company's stock has seen short-term gains, rising 13.9% over 30 days, reflecting a reset in investor expectations and a focus on future …

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) has received a "Moderate Buy" consensus recommendation from brokerages, based on seven buy ratings and one sell rating. The average 1-year price target is $24.80, significantly above its current trading price of $8.82. The company, which is focused on developing …

Abbott Laboratories (ABT) Impulsó Sus Ventas, ¿Sigue Infravalorada?

Abbott Laboratories Revenue Breakdown – NYSE:ABT

Abbott wins dismissal of shareholder lawsuit over 2022 infant formula recall

A federal judge in Chicago has dismissed a lawsuit against Abbott Laboratories that accused the company of defrauding shareholders regarding its 2022 infant formula recall. The judge stated that despite a lengthy complaint, shareholders failed to adequately present claims against Abbott or individual defendants.

ABT|Abbott Laboratories|Kurs:108.442|Änderung %:+0.632

Abbott India Limited Revenue Breakdown – NSE:ABBOTINDIA

ABT|Abbott Laboratories|Price:107.810|Chg%:-0.150

Abbott Laboratories stock trades steady as diagnostics and medical devices support earnings momentum

Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …

Abbott Stock And 2 Dividend Ideas For Retirement Income

This article explores three dividend stocks—Abbott Laboratories (ABT), Yü Group (AIM:YU.), and Artesian Resources (ARTN.A)—as potential retirement income sources, especially in light of Social Security reform concerns. It analyzes each company's overview, operations, market cap, and investment considerations, highlighting their strengths and risks for …

Abbott Faces Joint Spinal Cord Stimulator Lawsuit Filed by 17 Patients

Seventeen patients have filed a joint product liability lawsuit against Abbott Laboratories, alleging that its spinal cord stimulator (SCS) systems were defective, failed to alleviate chronic pain, and caused painful neurological complications. The lawsuit claims that Abbott misrepresented the safety and approval status of …

Receita da Abbott atinge US$ 12,59 bilhões no 2T2026

Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating

Daiwa Securities has adjusted its price target for Abbott Laboratories (ABT) to $103 from $92, while maintaining a Neutral rating on the stock. This adjustment comes amidst other analyst revisions for Abbott Laboratories, with several firms raising their price targets and maintaining positive ratings. …

Abbott Laboratories (ABT) Is Up 12.7% After Revenue Rises But Earnings Shrink In Q2 2026

Abbott Laboratories reported increased sales in Q2 2026 and for the first half of the year, but experienced a significant drop in net income and diluted earnings per share. This performance raises questions about cost pressures and profitability, leading to a focus on cost …

Abbott Laboratories (ABT) Earnings Drew Fresh Attention, Is It Still Below Fair Value?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Abbott Laboratories earnings put recent stock moves in context Abbott Laboratories (ABT) is back in focus after its latest quarterly earnings, where higher year over …

Abbott (ABT) Stock May Be 32% Undervalued As Legal Overhang Fades

Abbott Laboratories (ABT) stock appears undervalued by roughly 32% according to Discounted Cash Flow (DCF) analysis and a tailored P/E ratio, despite trading at a premium to some industry averages. The valuation considers the company's shift towards higher-margin MedTech and diagnostics, including cancer and …

Abbott: EPS-Prognose auf 5,45–5,60 Dollar erhöht

Patients sue diagnostics company over data breach

A class action lawsuit has been filed against Abbott Laboratories and its subsidiary Exact Sciences by Illinois patients, alleging the companies failed to adequately protect their sensitive data from a ransomware attack. The breach, for which the cybercriminal group ShinyHunters claimed responsibility, reportedly compromised …

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of infant formula, medical devices …

Lobbying Update: $1,150,000 of ABBOTT LABORATORIES lobbying was just disclosed

Abbott Laboratories disclosed $1,150,000 in lobbying expenditures for Q2 2026, covering issues such as healthcare legislation, trade agreements, data privacy, and medical device regulations. The report also details recent insider trading activities, congressional stock trades involving ABT, hedge fund adjustments to their holdings, and …

This Dividend King Could Be One of the Safest Stocks to Own Right Now

A gold crown with sparkling dust by tomertu via Shutterstock Choosing the right dividend stock isn't just about chasing the highest yields. The best dividend stocks are often the ones that quietly raise their payouts year after year while continuing to grow the underlying …

Healthcare giant Abbott probes two cyber incidents amid extortion claims

Abbott Laboratories is investigating two separate cyber incidents, one affecting its Cancer Diagnostics business and another involving its LabCentral customer portal. While Abbott asserts no impact on manufacturing or patient care and denies sensitive customer data exposure through LabCentral, cybercriminal groups ShinyHunters and ShadowByt3$ …

Only Three Days Left To Cash In On Abbott India's (NSE:ABBOTINDIA) Dividend

Abbott Laboratories Cybersecurity Breach Analysis: ShinyHunters Attack on Exact Sciences Systems and ShadowByt3$ LabCentral Portal Incident

Abbott Laboratories is investigating two cybersecurity incidents: one involving the ShinyHunters group compromising legacy Exact Sciences systems and exfiltrating data via a vishing campaign, and another focusing on the LabCentral customer portal, with ShadowByt3$ claiming to have stolen technical documentation. While ShinyHunters threatened public …

Abbott Laboratories (ABT) Stock Faces Margin Squeeze As Net Profit Slide Tests Growth Narrative

Abbott Laboratories (ABT) recently reported Q2 2026 earnings with robust revenue growth but a significant drop in net profit margins from 32.4% to 11.6%. While consensus forecasts anticipate higher profit margins and 16.7% annual earnings growth, the current lower margin base and 7.9% trailing …

Abbott Laboratories Stock Surges 11% as Company Lifts Full Year Profit Guidance

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded by Wall Street Zen to "Sell" Rating

Wall Street Zen has upgraded BridgeBio Oncology Therapeutics (NASDAQ:BBOT) from a "strong sell" to a "sell" rating, while the overall analyst consensus remains a "Moderate Buy" with an average target price of $24.80. The company reported a significant loss per share for its latest …

Abbott investigates two separate cyber incidents, says no operations affected

Abbott Laboratories is investigating two distinct cyber incidents involving unauthorized access to internal systems at its cancer diagnostics business and its LabCentral portal. The company stated that no operations were affected, no other businesses or systems were impacted, and there was no known exposure …

Abbott probes two cyber incidents amid extortion claims

Abbott Laboratories is investigating two separate cybersecurity incidents. One involves the ShinyHunters extortion group, which claims to have stolen data from Abbott's Cancer Diagnostics business systems through a vishing attack. The second incident involves the threat actor ShadowByt3$, who claims to have breached Abbott's …

Abbott discloses cyberattack on cancer diagnostics business

Abbott has disclosed a cyberattack impacting a limited number of internal systems within its cancer diagnostics business. The company confirmed that other Abbott businesses, sites, or systems were not affected, and there was no impact on operations, products, or patient services. An investigation is …

These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories reported strong second-quarter results, surpassing analyst expectations for both adjusted earnings and revenue, and subsequently raised its full-year adjusted earnings guidance. Following this positive news, analysts from BTIG and Evercore ISI Group increased their price targets for Abbott stock, while RBC Capital …

Can Abbott Stock Deliver on Its Second-Half Growth Promise?

Abbott Laboratories (ABT) stock has fallen 23% this year but management forecasts a significant second-half growth acceleration, raising its full-year profit outlook. Investors are faced with the challenge of betting on this predicted surge, relying on a turnaround in various divisions and successful new …

Abbott Laboratories (NYSE:ABT) Surprises With Q2 CY2026 Sales

Abbott Laboratories (NYSE:ABT) exceeded Wall Street's revenue and adjusted EPS expectations in Q2 CY2026, with sales up 13% year-on-year to $12.59 billion and non-GAAP profit reaching $1.31 per share. Despite a decrease in operating margin, the company's management raised its full-year Adjusted EPS guidance. …

Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance

Abbott (NYSE: ABT) announced its second-quarter 2026 financial results, reporting substantial growth and raising its full-year EPS guidance. The company achieved 13.0 percent reported sales growth and 4.8 percent comparable sales growth, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. …

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Abbott Laboratories' Q2 earnings report has reassured Wall Street, demonstrating that its integration of Exact Sciences is progressing better than anticipated, leading to solid growth and improved profitability metrics. The company reported 13% growth and 4.8% organic growth, exceeding adjusted EPS forecasts and prompting …